{"commentary":{"count":7,"free_build_floor":8,"listing_floor":3,"by_channel":{"youtube":5,"podcast":2},"note":"Indexed podcasts, YouTube videos and X posts that name this trial. A report screens them, searches for more and cites what clinicians said when it is built."},"free_build":{"available":false},"name":"NCT05256225","nct_id":"NCT05256225","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=nct05256225. The price is fixed at order. We build the report after the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–12 commentary sources"},"registry":{"acronym":null,"arms":[{"description":"Patients receive paclitaxel IV over 3 hours and carboplatin IV over 30-60 minutes on day 1 of each cycle. Cycles repeat every 3 weeks for 6 cycles in the absence of disease progression or unacceptable toxicity. Patients with SD or PR who still have measurable disease after completion of cycle 6 may receive 4 additional cycles of this treatment at the discretion of the treating physician.\n\nPatients undergo ECHO or MUGA and CT throughout the study. Additionally, patients may optionally undergo blood sample collection throughout the study, vaginal brachytherapy on study, and urine sample collection prior to treatment.","label":"Arm I (paclitaxel, carboplatin)","type":"ACTIVE_COMPARATOR"},{"description":"Patients receive paclitaxel IV over 3 hours, carboplatin IV over 30-60 minutes, and trastuzumab/hyaluronidase-oysk SC over 2-5 minutes on day 1 of each cycle. Cycles repeat every 3 weeks for 6 cycles in the absence of disease progression or unacceptable toxicity. Patients with SD or PR who still have measurable disease after completion of cycle 6 may receive 4 additional cycles of this treatment at the discretion of the treating physician.\n\nMAINTENANCE: Patients receive trastuzumab/hyaluronidase-oysk SC over 2-5 minutes on day 1 of each cycle. Cycles repeat every 3 weeks for up to 1 year in the absence of disease progression or unacceptable toxicity. Patients with SD or PR may continue maintenance therapy for up to 3 years from the start of treatment.\n\nPatients undergo ECHO or MUGA and CT throughout the study. Additionally patients may optionally undergo blood sample collection throughout the study, vaginal brachytherapy on study, and urine sample collection prior to treatment.","label":"Arm II (paclitaxel, carboplatin, Herceptin Hylecta)","type":"EXPERIMENTAL"},{"description":"See Detailed Description.","label":"Arm III (paclitaxel, carboplatin, Phesgo)","type":"EXPERIMENTAL"}],"collaborators":["NRG Oncology"],"completion_date":{"date":"2027-10-31","type":"ESTIMATED"},"conditions":["Endometrial Carcinoma","Endometrial Clear Cell Adenocarcinoma","Endometrial Dedifferentiated Carcinoma","Endometrial Endometrioid Adenocarcinoma","Endometrial Mixed Cell Adenocarcinoma","Endometrial Serous Adenocarcinoma","Endometrial Undifferentiated Carcinoma","Uterine Corpus Malignant Mixed Mesodermal (Mullerian) Tumor"],"enrollment":{"count":360,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"Biospecimen Collection","type":"PROCEDURE"},{"name":"Carboplatin","type":"DRUG"},{"name":"Computed Tomography","type":"PROCEDURE"},{"name":"Echocardiography Test","type":"PROCEDURE"},{"name":"High-Dose-Rate Vaginal Cuff Brachytherapy","type":"RADIATION"},{"name":"Hyaluronidase-zzxf/Pertuzumab/Trastuzumab","type":"DRUG"},{"name":"Multigated Acquisition Scan","type":"PROCEDURE"},{"name":"Paclitaxel","type":"DRUG"},{"name":"Survey Administration","type":"OTHER"},{"name":"Trastuzumab/Hyaluronidase-oysk","type":"DRUG"}],"last_update":"2026-10-02","lead_sponsor":"National Cancer Institute (NCI)","official_title":"A Phase II/III Study of Paclitaxel/Carboplatin Alone or Combined With Either Trastuzumab and Hyaluronidase-oysk (HERCEPTIN HYLECTA) or Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf (PHESGO) in HER2 Positive, Stage I-IV Endometrial Serous Carcinoma or Carcinosarcoma","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE3"],"primary_completion_date":{"date":"2027-10-31","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Progression free survival","timeFrame":"From study entry to time of progression or death, whichever occurs first, or date of last contact if neither progression nor death has occurred, assessed up to 5 years from randomization"},{"measure":"Overall survival","timeFrame":"From study entry to time of death or the date of last contact, assessed up to 5 years from randomization"},{"measure":"Incidence of dose limiting toxicities","timeFrame":"Up to end of cycle 3 (week 12)"}],"references":[{"citation":"Secord AA, Powell MA, McAlpine J. Molecular Characterization and Clinical Implications of Endometrial Cancer. Obstet Gynecol. 2025 Nov 1;146(5):660-671. doi: 10.1097/AOG.0000000000006080. Epub 2025 Sep 18.","pmid":"40966692","type":"DERIVED"}],"start_date":{"date":"2022-11-16","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma","url":"https://clinicaltrials.gov/study/NCT05256225"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"2.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/nct05256225"}